ANIK Q1 2024 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$213M

Q1 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$41M+6.9% YoY

Gross Profit

$25M60.8% margin

Operating Income

-$5M-12.5% margin

Net Income

-$5M-11.1% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

-5.7%

Cash Flow

Operating Cash Flow

-$126,000

Free Cash Flow

-$2M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$264M

Total Liabilities

$55M

Stockholders' Equity

$209M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$38M	+6.9%
Gross Profit	$25M	$23M	+7.8%
Operating Income	-$5M	-$13M	+59.7%
Net Income	-$5M	-$10M	+56.4%

Revenue Segments

Joint Preservation and Restoration

$14M85%

Non-Orthopedic

$2M15%

Geographic Segments

UNITED STATES

$29M83%

Europe

$6M17%